DBV Tech raises USD 150m as BLA imminent for peanut-allergy patch

DBV Technologies has [refreshed ](https://www.globenewswire.com/news-release/2026/07/17/3329305/0/en/DBV-Technologies-Files-At-The-Market-ATM-Prospectus-for-Up-to-150-Million-of-Sales.html)its at-the-market equity facility, restoring capacity to raise up to USD 150 million as the company prepares to submit a BLA for its VIASKIN Peanut Patch. The filing replenishes an ATM program originally established in 2025 after DBV drew approximately USD 65 million from the facility to support manufacturing, regulatory activities, and commercial preparation. Proceeds are earmarked for manufacturing expansion, BLA-related activities across both of DBV's pediatric peanut-allergy indications, and launch preparation for the 4-7-year-old population, if approved. The company's most recent [quarterly update](https://app.allsci.com/news/ASC-NR-0000003853976-1.0-1782914439?query=DBV%20Technologies) disclosed cash and equivalents of USD 174.9 million as of June 30, 2026, providing runway into the third quarter of 2027, but R\&D and SG\&A expenses have risen sharply as the company builds US commercial infrastructure ahead of a potential launch. VIASKIN Peanut Patch is an epicutaneous immunotherapy delivering peanut allergen through intact skin to desensitize allergic children. The [Phase III VITESSE trial](https://clinicaltrials.gov/study/NCT05741476) in children aged 4-7 met its primary endpoint in December 2025, with 46.6% of treated patients meeting responder criteria versus 14.8% on placebo. DBV had originally targeted a BLA filing in the first half of 2026 but pushed the timeline to the third quarter after extended, non-data-related discussions with the FDA over CMC and biostatistical data formatting. A separate BLA for toddlers aged 1-3, supported by the ongoing COMFORT Toddlers safety study, is expected in the second half of 2026. DBV's cash position has been bolstered by a March 2025 private placement worth up to USD 306.9 million (EUR 284.5 million), with warrant exercises tied to VITESSE's positive readout generating an additional USD 94 million in January 2026. There is no approved competitor in epicutaneous immunotherapy for peanut allergy; the standard of care remains oral immunotherapy products such as Aimmune's Palforzia, positioning VIASKIN as a differentiated, non-oral alternative if approved. The company's reliance on continued capital markets access—now including a fully refreshed ATM alongside its PIPE proceeds—underscores the scale of investment required to reach commercialization. *** Access the [AllSci platform](https://app.allsci.com/) to explore the science behind the news. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/peanut-allergy-patch-dbv-technologies-raises-usd)